Life Science Nation Newsletter | December 13, 2018 | Issue 296

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
   Life Science Investor Mandates
(Dec. 6 - Dec. 12 )
Invests in Digital and Diagnostic Innovation
Opens Evergreen Fund to Invest in Early Stage Oncology
Focuses on Advanced Materials in Healthcare
Invests in Clinical-Stage Devices, Diagnostics and Regenerative Medicine
LSN Services
LSN Videos
LSN Media Partners
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

LSN's Redefining Early Stage Investments (RESI) conference series is a unique one-of-a-kind partnering conference. RESI is a 100% dedicated investor and channel partner conference. By leveraging LSN's best-in-class Investor Database, RESI regularly delivers highly qualified global early stage life science investors with vetted investment mandates to a bevy of early stage CEOs seeking capital for the latest drugs, devices, diagnostics and digital health technologies (RESI is cross domain)  that they are developing. The RESI conference series has created a unique format that runs every few months, allowing both the fundraising CEOs and the investors to incorporate RESI into their month-to-month business schedules as a vehicle to start and continue dialogues and relationships, making RESI very sticky. LSN employs a high-touch partnering system, allowing investors and companies to search for partners who are a fit for them based on multiple citeria, making RESI partnering meetings extremely compelling and efficient for both the buy-side and sell-side.

Here are the key attributes of a RESI conference:

RESI Innovation Challenge - LSN has developed an expert system that stack-ranks technology assets, assessing their 'investibility' based on multiple criteria across many areas. Those who apply, and are selected, are featured in the exhibit hall of our RESI conference and tend to get amazing exposure with the investors and partners that attend. As a matter of fact, more than 50% of the RESI Innovation Challenge winners have been funded!

Partnering is key...

By Jessica Yang, Senior Investor Research Analyst & Asia BD, LSN

As more and more Asia-based companies are trying to enter the global market, RESI provides the stage for these companies to shine. This year, we are partnering with BioMed Taiwan to launch a luncheon at RESI JPM from 11:50 am - 1:00 pm at Marines' Memorial Club & Hotel (2nd floor), and you are invited to attend! This will be a great opportunity to network with international hubs and investors and explore the latest cutting-edge technologies from Taiwan. RSVP now to join the Taiwan Luncheon!

Marines' Memorial Club & Hotel 2nd floor Theater, 609 Sutter St, San Francisco, CA 94102

01/08/19 11:50am - 01/08/19 1:00pm

Check out the presenting Taiwan companies below:

By Lucy Parkinson, VP of Investor Research, LSN

Launch Collaboration to Provide Early Stage Funding for International Healthcare Startups  

The joint initiative between Life Science Nation (LSN) and Stetson Family Office (SFO) will:
  • Assist international life science startups in raising seed capital, series A and B funding rounds, and offer a Boston-based immersion fundraising and partnering program.
  • Prepare and integrate these startups into LSN's global partnering ecosystem, including the Redefining Early Stage Investments (RESI) Conference Series in Boston, San Francisco, Europe and Asia and access to LSN's partner network.
  • Use family office philanthropic and impact investment strategies, along with angel investors' expertise, in seed rounds to move compelling technology out of the labs and onto the commercial development path. It will focus specifically on years 0 to 3, commonly referred to as "The Valley of Death".
  • Advance women as investors and as entrepreneurs in the life sciences.
  • Direct preliminary interest in products that impact healthy brain, diabetes, obesity and heart disease, although all products are welcome...

Created & Produced by